Aquestive Therapeutics Inc

NASDAQ:AQST   3:59:56 PM EDT
6.72
-0.17 (-2.47%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)225.92M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$6.54 Million
Adjusted EPS-$0.51
See more estimates
10-Day MA$6.72
50-Day MA$5.71
200-Day MA$5.20
See more pivots

Aquestive Therapeutics, Inc. Stock, NASDAQ:AQST

30 TECHNOLOGY DRIVE, WARREN, NJ 07059
United States of America
Phone: 908-941-1900
Number of Employees: 277

Description

Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors. It also develops AQST-119, an oral soluble film formulation of tadalafil for the treatment of erectile dysfunction; and APL-130277, a sublingual film using apomorphine to treat parkinson's disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.